TTP 273

Drug Profile

TTP 273

Alternative Names: TTP-273

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator vTv Therapeutics
  • Developer vTv Therapeutics LLC
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 27 Feb 2018 vTv Therapeutics plans a phase II trial in Type-2 diabetes mellitus in China, Pacific Rim countries and USA
  • 21 Dec 2017 TTP 273 licensed to Hangzhou Zhongmei Huadong Pharmaceutical in China, Hong Kong, Macau, Taiwan, Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei, South Korea and Australia
  • 11 Jun 2017 Updated adverse events data from the phase II LOGRA trial in Type-2 diabetes mellitus released by vTv Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top